Introduction {#sec1}
============

Neuroblastoma is a neuroendocrine tumor that originates from the developing sympathetic nervous system. It is the most common solid malignancy in the first year of life, accounting for approximately 15% of pediatric cancer deaths \[[@B1]\]. Despite remarkable advances in multimodality treatment, the survival rate for patients with high-risk tumors remains approximately 50% \[[@B1],[@B2]\]. At present, the etiology of neuroblastoma remains far from clear. Genetic variations have been shown to be important factors in the origination and development of neuroblastoma \[[@B3]\]. A previous genome-wide association study (GWAS) demonstrated that common genetic variations in the *BARD1* gene may contribute to the etiology of the aggressive neuroblastoma \[[@B6]\]. Moreover, polymorphisms in the *CDKN1B* gene were found to associate with neuroblastoma susceptibility \[[@B7]\]. Over the past years, several GWASs have identified a number of genetic alterations that not only influence neuroblastoma formation but also contribute to malignant transformation \[[@B8]\]. Single nucleotide polymorphisms (SNPs) within *DDX4, HSD17B12*, and *DUSP12* are recurrent in low-risk neuroblastoma \[[@B11],[@B12]\]. SNPs in *CASC15, LMO1*, and *LIN28B* are enriched in high-risk neuroblastoma and are correlated with neuroblastoma tumor aggressiveness \[[@B10],[@B13],[@B14]\]. Previous study demonstrated that LIN28B promotes *AURKA* expression via inhibition of let-7, further driving neuroblastoma oncogenesis \[[@B15]\].

*AURKA*, located at chromosome region 20q13.2, encodes a serine/threonine kinase (Aurora-A) that has been shown to play a crucial role in regulating mitosis. Overexpression of Aurora-A contributes to centrosomal duplication abnormalities, genomic instability, and the promotion of tumorigenesis \[[@B16],[@B17]\]. Over the past decade, Aurora-A overexpression has been demonstrated in multiple human cancers, including primary colorectal carcinoma, esophageal squamous cell carcinoma, and breast and ovarian cancers \[[@B17]\]. And overexpression of Aurora-A is associated with advanced clinical states, worse overall survival, and shorter event-free survival in patients with neuroblastoma \[[@B20]\]. In addition, several studies confirmed that *AURKA* polymorphisms were associated with the risk of several human cancers \[[@B21]\]. To date, no study has assessed the associations between *AURKA* SNPs and the risk of neuroblastoma.

To evaluate the associations between the SNPs in the *AURKA* gene and neuroblastoma susceptibility, we conducted this case--control study with 393 neuroblastoma cases and 812 control subjects from the Chinese population.

Materials and methods {#sec2}
=====================

Study subjects {#sec2-1}
--------------

In the present study, a total of 393 neuroblastoma cases and 812 controls were recruited from two different regions of China \[[@B25]\]. The first population was composed of 275 neuroblastoma cases and 531 controls from the Guangzhou Women and Children's Medical Center \[[@B29]\]. The second population consisted of 118 neuroblastoma cases and 281 controls from The First Affiliated Hospital of Zhengzhou University \[[@B32],[@B33]\]. Both the cases and controls were of Chinese Han ethnicity and were genetically unrelated. The cases and controls were matched according to age, gender, and ethnicity. Neuroblastoma patients were diagnosed by biopsy and staged according to the International Neuroblastoma Staging System (INSS) \[[@B34]\]. The present study was approved by the Institutional Review Board of each institution. Written informed consent was acquired from the parents or guardians of each participant.

Polymorphism selection and genotyping {#sec2-2}
-------------------------------------

Polymorphisms were chosen based on the following criteria: (i) minor allele frequency \>5% for CHB subjects; (ii) potentially functional as predicted by SNPinfo (<http://snpinfo.niehs.nih.gov/>) software; (iii) not investigated for the association with neuroblastoma susceptibility. We searched the potentially functional polymorphisms located in the 5′-flanking region, 5′ UTR, 3′ UTR, and exon of *AURKA* gene*.* Three SNPs (rs1047972 C\>T, rs2273535 T\>A, and rs8173 G\>C) in the *AURKA* gene were selected (Supplementary Table S1). These three SNPs can capture additional fourteen SNPs. As shown in Supplementary Figure S1, there was no significant linkage disequilibrium between paired polymorphisms (*R^2^* = 0.119 between rs8173 and rs1047972; *R^2^* = 0.527 between rs8173 and rs2273535; and the *R^2^* = 0.291 between rs1047972 and rs2273535). These SNPs were genotyped using TaqMan real-time PCR following a published protocol \[[@B35]\]. To ensure credible genotyping results, 10% of the samples were randomly selected for repeated genotyping assays, and the results were 100% concordant.

Statistical analysis {#sec2-3}
--------------------

Differences in genotype frequencies as well as in demographic variables between cases and controls were compared by two-sided χ^2^ tests. Hardy--Weinberg equilibrium (HWE) for the genotype frequencies in controls was calculated by a goodness-of-fit χ^2^ test. Associations between *AURKA* SNPs and neuroblastoma were estimated using adjusted odds ratios (ORs) and 95% confidence intervals (CIs). We also performed analyses stratified by age, gender, tumor sites, and clinical stages. *P*\<0.05 was considered statistically significant. All statistical tests were performed using SAS software (version 9.4; SAS Institute, Cary, NC, U.S.A.).

Results {#sec3}
=======

AURKA gene polymorphisms and neuroblastoma susceptibility {#sec3-1}
---------------------------------------------------------

In the present study, 393 cases and 812 controls were successfully genotyped. The genotype frequencies of the three *AURKA* polymorphisms and their associations with neuroblastoma susceptibility are summarized in [Table 1](#T1){ref-type="table"}. The observed genotype frequencies amongst the control subjects were in HWE (*P*=0.337 for the rs1047972 C\>T polymorphism, *P*=0.174 for the rs2273535 T\>A polymorphism, and *P*=0.506 for the rs8173 G\>C polymorphism). No significant associations were identified between any of the three *AURKA* SNPs and the risk of neuroblastoma.

###### The correlation of *AURKA* gene polymorphisms with neuroblastoma risk

  Genotype                                                                         Cases (*n*=393)   Controls (*n*=812)   *P* [^1^](#T1TFN1){ref-type="table-fn"}   Crude OR (95% CI)   *P*     Adjusted OR (95% CI)[^2^](#T1TFN2){ref-type="table-fn"}   *P* [^2^](#T1TFN2){ref-type="table-fn"}
  -------------------------------------------------------------------------------- ----------------- -------------------- ----------------------------------------- ------------------- ------- --------------------------------------------------------- -----------------------------------------
  **rs1047972 C\>T (HWE = 0.337)**                                                                                                                                                                                                                        
    CC                                                                             305 (77.61)       629 (77.46)                                                    1.00                        1.00                                                      
    CT                                                                             87 (22.14)        168 (20.69)                                                    1.07 (0.80--1.43)   0.660   1.07 (0.80--1.43)                                         0.671
    TT                                                                             1 (0.25)          15 (1.85)                                                      0.14 (0.02--1.05)   0.055   0.14 (0.02--1.04)                                         0.055
  **Additive**                                                                                                            0.070                                     0.92 (0.70--1.20)   0.535   0.92 (0.70--1.20)                                         0.526
    Dominant                                                                       88 (22.39)        183 (22.54)          0.955                                     0.99 (0.74--1.32)   0.955   0.99 (0.74--1.32)                                         0.943
    Recessive                                                                      392 (99.75)       797 (98.15)          0.024                                     0.14 (0.02--1.03)   0.053   0.14 (0.02--1.03)                                         0.053
  **rs2273535 T\>A (HWE = 0.174)**                                                                                                                                                                                                                        
    TT                                                                             182 (46.31)       377 (46.43)                                                    1.00                        1.00                                                      
    TA                                                                             171 (43.51)       340 (41.87)                                                    1.04 (0.81--1.35)   0.753   1.04 (0.81--1.34)                                         0.765
    AA                                                                             40 (10.18)        95 (11.70)                                                     0.87 (0.58--1.31)   0.513   0.87 (0.58--1.31)                                         0.511
  **Additive**                                                                                                            0.699                                     0.97 (0.81--1.16)   0.735   0.97 (0.81--1.16)                                         0.728
    Dominant                                                                       211 (53.69)       435 (53.57)          0.969                                     1.01 (0.79--1.28)   0.969   1.00 (0.79--1.28)                                         0.981
    Recessive                                                                      353 (89.82)       717 (88.30)          0.433                                     0.86 (0.58--1.26)   0.433   0.86 (0.58--1.27)                                         0.435
  **rs8173 G\>C (HWE = 0.506)**                                                                                                                                                                                                                           
    GG                                                                             164 (41.73)       314 (38.67)                                                    1.00                        1.00                                                      
    GC                                                                             176 (44.78)       389 (47.91)                                                    0.87 (0.67--1.12)   0.278   0.86 (0.67--1.12)                                         0.265
    CC                                                                             53 (13.49)        109 (13.42)                                                    0.93 (0.64--1.36)   0.711   0.93 (0.64--1.36)                                         0.698
  **Additive**                                                                                                            0.555                                     0.94 (0.78--1.12)   0.473   0.94 (0.78--1.12)                                         0.458
    Dominant                                                                       229 (58.27)       498 (61.33)          0.309                                     0.88 (0.69--1.13)   0.309   0.88 (0.69--1.12)                                         0.294
    Recessive                                                                      340 (86.51)       703 (86.58)          0.976                                     1.01 (0.71--1.43)   0.976   1.00 (0.71--1.43)                                         0.981
  **Combined effect of protective genotypes**[^3^](#T1TFN3){ref-type="table-fn"}                                                                                                                                                                          
    0                                                                              162 (41.22)       312 (38.42)                                                    1.00                        1.00                                                      
    1--3                                                                           231 (58.78)       500 (61.58)          0.351                                     0.89 (0.70--1.14)   0.351   0.89 (0.69--1.13)                                         0.335

*χ^2^* test for genotype distributions between neuroblastoma patients and cancer-free controls.

Adjusted for age and gender.

Protective genotypes were rs1047972 TT, rs2273535 AA, and rs8173 GC/CC.

Stratification analysis {#sec3-2}
-----------------------

We then divided participants into subgroups according to age, gender, clinical stage, and site of origin. The effects of the selected polymorphisms on the risk of neuroblastoma were assessed in this stratified analysis ([Table 2](#T2){ref-type="table"}). The effects of combined risk genotypes on neuroblastoma risk were also assessed. However, no significant association was discovered for any of the selected polymorphisms.

###### Stratification analysis for association between *AURKA* gene genotypes and neuroblastoma susceptibility

  Variables             rs1047972 (case/control)   AOR (95% CI)   *P* [^1^](#T2TFN1){ref-type="table-fn"}   rs2273535 (case/control)   AOR (95% CI)   *P* [^1^](#T2TFN1){ref-type="table-fn"}   rs8173 (case/control)   AOR (95% CI)   *P*[^1^](#T2TFN1){ref-type="table-fn"}   Protective genotypes (case/control)   AOR (95% CI)         *P*[^1^](#T2TFN1){ref-type="table-fn"}                                           
  --------------------- -------------------------- -------------- ----------------------------------------- -------------------------- -------------- ----------------------------------------- ----------------------- -------------- ---------------------------------------- ------------------------------------- -------------------- ---------------------------------------- --------- --------- ------------------- -------
  **Age, months**                                                                                                                                                                                                                                                                                                                                                                                                           
  ≤18                   103/241                    23/64          0.84 (0.50--1.43)                         0.522                      64/147         62/158                                    0.90 (0.60--1.37)       0.624          59/132                                   67/173                                0.87 (0.57--1.32)    0.501                                    59/130    67/175    0.84 (0.56--1.28)   0.425
  \>18                  202/388                    65/119         1.05 (0.74--1.48)                         0.789                      118/230        149/277                                   1.05 (0.78--1.41)       0.759          105/182                                  162/325                               0.86 (0.64--1.17)    0.344                                    103/182   164/325   0.89 (0.66--1.21)   0.458
  **Gender**                                                                                                                                                                                                                                                                                                                                                                                                                
  Female                130/269                    38/73          1.09 (0.70--1.70)                         0.715                      77/161         91/181                                    1.06 (0.73--1.53)       0.773          67/139                                   101/203                               1.05 (0.72--1.53)    0.821                                    66/138    102/204   1.06 (0.72--1.55)   0.772
  Male                  175/360                    50/110         0.93 (0.64--1.36)                         0.711                      105/216        120/254                                   0.97 (0.70--1.33)       0.834          97/175                                   128/295                               0.78 (0.56--1.07)    0.123                                    96/174    129/296   0.78 (0.57--1.08)   0.136
  **Sites of origin**                                                                                                                                                                                                                                                                                                                                                                                                       
  Adrenal gland         118/629                    35/183         1.00 (0.66--1.51)                         0.999                      67/377         86/435                                    1.09 (0.77--1.55)       0.623          56/314                                   97/498                                1.06 (0.74--1.51)    0.768                                    55/312    98/500    1.08 (0.75--1.54)   0.696
  Retroperitoneal       68/629                     19/183         0.96 (0.57--1.65)                         0.894                      40/377         47/435                                    1.02 (0.75--1.59)       0.941          38/314                                   49/498                                0.82 (0.52--1.28)    0.381                                    37/312    50/500    0.85 (0.54--1.33)   0.476
  Mediastinum           87/629                     22/183         0.88 (0.54--1.45)                         0.621                      55/377         54/435                                    0.86 (0.58--1.28)       0.460          52/314                                   57/498                                0.71 (0.47--1.06)    0.090                                    52/312    57/500    0.70 (0.47--1.04)   0.080
  Others                27/629                     9/183          1.14 (0.53--2.47)                         0.737                      17/377         19/435                                    0.97 (0.50--1.89)       0.922          15/314                                   21/498                                0.90 (0.45--1.77)    0.750                                    15/312    21/500    0.88 (0.45--1.75)   0.723
  **Clinical stage**                                                                                                                                                                                                                                                                                                                                                                                                        
  I + II + 4s           131/629                    31/183         0.82 (0.54--1.26)                         0.367                      80/377         82/435                                    0.90 (0.64--1.26)       0.520          77/314                                   85/498                                0.71 (0.50--0.996)   0.047                                    75/312    87/500    0.74 (0.52--1.04)   0.079
  III + IV              158/629                    53/183         1.14 (0.80--1.62)                         0.466                      93/377         118/435                                   1.09 (0.80--1.48)       0.573          77/314                                   134/498                               1.07 (0.78--1.47)    0.660                                    77/312    134/500   1.06 (0.78--1.46)   0.699

Abbreviation: AOR, adjusted OR.

Adjusted for age and gender, omitting the corresponding stratify factor.

Discussion {#sec4}
==========

We conducted the present case--control study with a total of 393 neuroblastoma patients and 812 control subjects to investigate the impact of three *AURKA* SNPs on the risk of neuroblastoma in Chinese populations. Our data indicated that none of the selected SNPs were associated with neuroblastoma susceptibility in two independent Chinese populations. To the best of our knowledge, this is the first study to investigate the association between neuroblastoma susceptibility and polymorphisms in the *AURKA* gene.

*AURKA* has been reported to be overexpressed in several human malignancies and encodes a serine/threonine kinase that is involved in the processes of proliferation, survival, invasion, and stemness in multiple types of cancer \[[@B17]\]. Several studies have demonstrated that *AURKA* SNPs were associated with the risk of cancer \[[@B21]\]. Lee at al. \[[@B39]\] identified an association between a genetic variant (rs2273535) in the *AURKA* gene and oral cancer. A recent study has demonstrated that *AURKA* SNPs (rs1047972 and rs2273535) increase the risk of oral squamous cell carcinoma \[[@B40]\]. In Malaysian Chinese, *AURKA* rs2273535 protected against breast cancer \[[@B41]\]. A meta-analysis suggested that *AURKA* rs1047972 is associated with a decreased breast cancer risk in Caucasians, while *AURKA* rs2273535 polymorphism is associated with an increased risk of breast cancer \[[@B23]\]. This finding indicates that the functions of *AURKA* SNPs may vary depending on the types of cancer and ethnic differences.

Aurora A is responsible for stabilizating N-myc in neuroblastoma. \[[@B17],[@B42]\]. A previous study demonstrated that LIN28B-RAN-AURKA axis is implicated in neuroblastoma oncogenesis. Aurora A overexpression in neuroblastoma is associated with advanced clinical states, *MYCN* amplification, disease relapse, and progression \[[@B43]\]. As a transcriptional regulator, *MYCN* (encoding N-myc) plays a crucial role during embryonic development. In addition, *MYCN* amplification, which is involved in the inhibition of both cell-cycle exit and normal differentiation, contributes to neuroblastoma initiation and progression \[[@B44]\]. Knockdown of *AURKA* has been shown to decrease N-myc protein levels and neuroblastoma cell proliferation \[[@B47]\]. However, we failed to detect any significant association between these *AURKA* SNPs (rs1047972 C\>T, rs2273535 T\>A, and rs8173 G\>C) and neuroblastoma susceptibility in the present study. The negative results might be attributed to the limited sample size. The relatively small sample size might not be large enough to detect an association.

Several limitations in our study should be mentioned. First, the sample size in the present study might not be large enough to draw accurate conclusions. Increasing the sample size would increase the power to detect risk variants and increase the credibility of any observed associations. Analyses with large sample sizes are essential to verify our results. Second, the etiology of neuroblastoma is complex and multifactorial. Several important factors such as dietary intake and living environment contribute to neuroblastoma pathogenesis. The results should be explained with caution, because these confounding factors were not included in the current study. Third, only three *AURKA* SNPs were investigated in our study. Other polymorphisms in the *AURKA* gene should be investigated in future study. Fourth, the genotype distribution in this hospital-based study may not reflect that in the general population, which would inevitably result in selection bias.

In summary, our study confirmed that none of the *AURKA* polymorphisms (rs1047972 C\>T, rs2273535 T\>A, and rs8173 G\>C) were associated with neuroblastoma susceptibility in two distinct Chinese populations. Future studies with larger sample sizes and different ethnicities are required to further clarify the effect of *AURKA* SNPs on the risk of neuroblastoma.
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